Mitoquinone attenuates blood-brain barrier disruption through Nrf2/PHB2/OPA1 pathway after subarachnoid hemorrhage in rats.

CONCLUSIONS: MitoQ attenuates blood-brain barrier disruption via Nrf2/PHB2/OPA1 pathway after SAH in rats. MitoQ may serve as a potential therapeutic strategy for SAH patients. PMID: 30779914 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30779914?dopt=Abstract

Source: Experimental Neurology - February 16, 2019 Category: Neurology Authors: Zhang T, Xu S, Wu P, Zhou K, Wu L, Xie Z, Xu W, Luo X, Li P, Ocak U, Ocak PE, Travis ZD, Tang J, Shi H, Zhang JH Tags: Exp Neurol Source Type: research